Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although a small decrease in survival and increase in tumor incidence was observed in
ATR
(+/-) mice,
ATR
(-/-) embryos die early in development, subsequent to the blastocyst stage and prior to 7.5 days p.c. In culture,
ATR
(-/-) blastocysts cells continue to cycle into mitosis for 2 days but subsequently fail to expand and die of caspase-dependent apoptosis. Importantly, caspase-independent chromosome breaks are observed in
ATR
(-/-) cells prior to widespread apoptosis, implying that apoptosis is caused by a loss of genomic integrity. These data show that
ATR
is essential for early embryonic development and must function in processes other than regulation of
p53
.
...
PMID:ATR disruption leads to chromosomal fragmentation and early embryonic lethality. 1069 32
Checkpoints of DNA integrity are conserved throughout evolution, as are the kinases ATM (Ataxia Telangiectasia mutated) and
ATR
(Ataxia- and Rad-related), which are related to phosphatidylinositol (PI) 3-kinase [1] [2] [3]. The ATM gene is not essential, but mutations lead to ataxia telangiectasia (AT), a pleiotropic disorder characterised by radiation sensitivity and cellular checkpoint defects in response to ionising radiation [4] [5] [6]. The
ATR
gene has not been associated with human syndromes and, structurally, is more closely related to the canonical yeast checkpoint genes rad3(Sp) and MEC1(Sc) [7] [8].
ATR
has been implicated in the response to ultraviolet (UV) radiation and blocks to DNA synthesis [8] [9] [10] [11], and may phosphorylate
p53
[12] [13], suggesting that ATM and
ATR
may have similar and, perhaps, complementary roles in cell-cycle control after DNA damage. Here, we report that targeted inactivation of
ATR
in mice by disruption of the kinase domain leads to early embryonic lethality before embryonic day 8.5 (E8.5). Heterozygous mice were fertile and had no aberrant phenotype, despite a lower
ATR
mRNA level. No increase was observed in the sensitivity of
ATR
(+/-) embryonic stem (ES) cells to a variety of DNA-damaging agents. Attempts to target the remaining wild-type
ATR
allele in heterozygous
ATR
(+/-) ES cells failed, supporting the idea that loss of both alleles of the
ATR
gene, even at the ES-cell level, is lethal. Thus, in contrast to the closely related checkpoint gene ATM,
ATR
has an essential function in early mammalian development.
...
PMID:Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. 1080 16
p53
plays a central role in the cellular response to DNA double-strand breaks (DSBs), and to DNA damage in general. The protein kinases ATM,
ATR
and DNA-PK detect DSBs and transmit this information to
p53
by phosphorylation. This phosphorylation dissociates
p53
from its negative regulator, mdm2.
p53
then undergoes further modification and activates transcription of the genes responsible for cell cycle arrest. In certain circumstances,
p53
also activates transcription of the genes responsible for apoptosis. The dysfunction of this cascade of events is oncogenic, with
P53
itself being the most commonly mutated gene in malignant cells, although mutations in both the DNA damage sensors and cell cycle checkpoint and apoptosis effectors are frequent. A more complete understanding of
p53
and the proteins it interacts with may allow the development of new cancer treatments.
...
PMID:[p53 activation by PI-3K family kinases after DNA double-strand breaks]. 1103 13
Posttranslational modifications of
p53
induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Although both drugs were able to induce phosphorylation at serine 20 (Ser20), only DDP treatment induced
p53
phosphorylation at serine 15 (Ser15). Moreover, both drug treatments were able to increase
p53
levels and consequently the transcription of waf1 and mdm-2 genes, although DDP treatment resulted in a stronger inducer of both genes. Using two ataxia telangiectasia mutated (ATM) cell lines, the role of ATM in drug-induced
p53
phosphorylations was investigated. No differences in drug-induced
p53
phosphorylation could be observed, indicating that ATM is not the kinase involved in these phosphorylation events. In addition, inhibition of DNA-dependent protein kinase activity by wortmannin did not abolish
p53
phosphorylation at Ser15 and Ser20, again indicating that DNA-PK is unlikely to be the kinase involved. After both taxol and DDP treatments, an activation of hCHK2 was found and this is likely to be responsible for phosphorylation at Ser20. In contrast, only DDP was able to activate
ATR
, which is the candidate kinase for phosphorylation of Ser15 by this drug. This data clearly suggests that differential mechanisms are involved in phosphorylation and activation of
p53
depending on the drug type.
...
PMID:Cisplatinum and taxol induce different patterns of p53 phosphorylation. 1132 11
Previous work has established a role for
p53
in triggering apoptosis in response to DNA damage;
p53
also induces apoptosis in response to deregulation of the Rb cell cycle pathway. The latter event is consistent with a role for the Rb-regulated E2F1 protein as a specific inducer of apoptosis and
p53
accumulation. We now show that DNA damage leads to a specific induction of E2F1 accumulation, dependent on ATM kinase activity and that the specificity of E2F1 induction reflects a specificity in the phosphorylation of E2F1 by ATM as well as the related kinase
ATR
. We identify a site for ATM/
ATR
phosphorylation in the amino terminus of E2F1 and we show that this site is required for ATM-mediated stabilization of E2F1. Finally, we also show that E2F1 is required for DNA damaged induced apoptosis in mouse thymocytes. We conclude that the cellular response to DNA damage makes use of signals from the Rb/E2F cell cycle pathway.
...
PMID:Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. 1145 32
Premature chromatin condensation (PCC) is a hallmark of mammalian cells that begin mitosis before completing DNA replication. This lethal event is prevented by a highly conserved checkpoint involving an unknown, caffeine-sensitive mediator. Here, we have examined the possible involvement of the caffeine-sensitive ATM and
ATR
protein kinases in this checkpoint. We show that caffeine's ability to inhibit
ATR
(but not ATM) causes PCC, that
ATR
(but not ATM) prevents PCC, and that
ATR
prevents PCC via Chk-1 regulation. Moreover, mimicking cancer cell phenotypes by disrupting normal G(1) checkpoints sensitizes cells to PCC by
ATR
inhibition plus low-dose DNA damage. Notably, loss of
p53
function potently sensitizes cells to PCC caused by
ATR
inhibition by a small molecule. We present a molecular model for how
ATR
prevents PCC and suggest that
ATR
represents an attractive therapeutic target for selectively killing cancer cells by premature chromatin condensation.
...
PMID:ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. 1148 75
We have isolated and characterized an isoform of protein kinase Chk1 gene from rat liver and a rat liver cDNA library by 5'-rapid amplification of cDNA ends. The gene (Cil) contains the C-terminal region of the Chk1 gene, but the 5'-end is derived from a sequence in the intron of Chk1 preceding the C-terminal domain by differential RNA splicing. The kinase domain of Chk1 gene is absent in this isoform. Tissue RNA and protein blot analyses indicated that Cil was specifically expressed only in rat liver, and its expression increased with liver development. Expression of Cil was found to be reduced in three rat hepatoma cell lines examined. A promoter trap experiment suggested that a promoter was located in the intron preceding the C-terminal domain of Chk1, and transcription from this novel promoter generated the new 5' noncoding exon of Cil. Thus Cil was generated by both alternate promoter usage and differential RNA splicing. UV irradiation induced caffeine-sensitive phosphorylation of both Chk1 and Cil at Ser-345 in Chk1 and its equivalent site in Cil, implying a role for
ATR
kinase in the phosphorylation of both proteins. We demonstrated the interaction between the kinase domain of Chk1 and Cil using a yeast two-hybrid assay and pull-down technique. In contrast to the effect of Chk1, Cil was found to decrease the transactivating function of
p53
, and the S63A mutation of Cil abolished this effect. These results suggest that Cil may serve as a dominant negative competitor of Chk1 as suggested previously.
...
PMID:Cloning and characterization of liver-specific isoform of Chk1 gene from rat. 1168 78
ATR
(ataxia telangiectasia and Rad-3-related) is a protein kinase required for survival after DNA damage. A critical role for
ATR
has been hypothesized to be the regulation of
p53
and other cell cycle checkpoints.
ATR
has been shown to phosphorylate
p53
at Ser(15), and this damage-induced phosphorylation is diminished by expression of a catalytically inactive (
ATR
-kd) mutant.
p53
function could not be examined directly in prior studies of
ATR
, however, because
p53
was mutant or because cells expressed the SV40 large T antigen that blocks
p53
function. To test the interactions of
ATR
and
p53
directly we generated human U2OS cell lines inducible for either wild-type or kinase-dead
ATR
that also have an intact
p53
pathway. Indeed,
ATR
-kd expression sensitized these cells to DNA damage and caused a transient decrease in damage-induced serine 15 phosphorylation of
p53
. However, we found that the effects of
ATR
-kd expression do not result in blocking the response of
p53
to DNA damage. Specifically, prior
ATR
-kd expression had no effect on DNA damage-induced
p53 protein
up-regulation,
p53
-DNA binding, p21 mRNA up-regulation, or G(1) arrest. Instead of promoting survival via
p53
regulation, we found that
ATR
protects cells by delaying the generation of mitotic phosphoproteins and inhibiting premature chromatin condensation after DNA damage or hydroxyurea. Although
p53
inhibition (by E6 or MDM2 expression) had little effect on premature chromatin condensation, when combined with
ATR
-kd expression there was a marked loss of the replication checkpoint. We conclude that
ATR
and
p53
can function independently but that loss of both leads to synergistic disruption of the replication checkpoint.
...
PMID:ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. 1171 32
Solar UVA, but not UVC, reaches the earth's surface and therefore is an important etiological factor for the induction of human skin cancer. ATM kinase is an important regulator of cell survival and cell cycle checkpoints. Here, we observe that UVA, unlike UVC, triggers ATM kinase activity, and the activation may occur through reactive oxygen species produced after irradiation of cells with UVA. We also show that ATM activation is involved in the apoptotic response to UVA but not UVC. Furthermore, we provide evidence that ATM-dependent
p53
and c-Jun N-terminal kinase (JNK) pathways are linked to UVA-induced apoptosis. On the other hand, UVC-induced apoptosis occurs through
ATR
-dependent
p53
phosphorylation as well as the JNK pathway. Therefore, these results suggest that ATM, like
p53
, is involved in the UVA-induced apoptosis to suppress carcinogenesis.
...
PMID:Requirement of ATM in UVA-induced signaling and apoptosis. 1172 37
We have investigated the mechanism of S-phase arrest elicited by the carcinogen benzo(a)pyrene dihydrodiol epoxide (BPDE) in
p53
-deficient cells. Inhibition of DNA synthesis after BPDE treatment was rapid and dose dependent (approximately 50% inhibition after 2 h with 50 nM BPDE). Cells treated with low doses (50-100 nM) of BPDE resumed DNA synthesis after a delay of approximately 4-8 h, whereas cells that received high doses of BPDE (600 nM) failed to recover from S-phase arrest. The checkpoint kinase Chk1 (but not Chk2) was phosphorylated after treatment with low doses of BPDE. High concentrations of BPDE elicited phosphorylation of both Chk1 and Chk2. Adenovirus-mediated expression of "dominant-negative" Chk1 (but not dominant-negative Chk2) and the Chk1 inhibitor UCN-01 abrogated the S-phase delay elicited by low doses of BPDE. Consistent with a role for the caffeine-sensitive ATM or
ATR
protein kinase in low-dose BPDE-induced S-phase arrest, both Chk1 phosphorylation and S-phase arrest were abrogated by caffeine. However, low doses of BPDE elicited Chk1 phosphorylation and S-phase arrest in AT cells (from ataxia telangiectasia patients), demonstrating that ATM is dispensable for S-phase checkpoint responses to this genotoxin. BPDE-induced Chk1 phosphorylation and S-phase arrest were abrogated by caffeine treatment in AT cells, suggesting that a caffeine-sensitive kinase other than ATM is an important mediator of responses to BPDE-adducted DNA. Overall, our data demonstrate the existence of a caffeine-sensitive, Chk1-mediated, S-phase checkpoint that is operational in response to BPDE.
...
PMID:Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. 1186 11
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>